[6]Rüschoff J, Friedrich M, Nagelmeier I, et al. Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status. Virchows Arch 2022;481:685-94. [7]Zhang H, Katerji H...
3.Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15(8):2894–904. 4.Shui R, Liang X, Li X, Liu Y, Li H...
虽然在乳腺癌中,主要是HER2高表达让癌细胞有过度增殖的能力,但是HER2基因的的突变也同样会让细胞癌化。在上世纪80年代初,Robert Weinberg和 Mark Greene 实验室研究了癌基因neu,这实际就是大鼠的her2基因,正常基因和癌基因的差异,只是HER2蛋白跨膜区的一个氨基酸残基发生了突变[1]。 大鼠中的这个癌基因突变,在人类...
[8]Ruschoff J, Friedrich M, Nagelmeier I, et al. Comparison of HercepTest ¨ TM mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status. Virchows Arch. 2022;481(5):685–694. [9]Fernandez ...
Atallah NM, Haque M, Quinn C, Toss MS, Makhlouf S, Ibrahim A, Green AR, Alsaleem M, Rutland CS, Allegrucci C, Mongan NP, Rakha E. Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression. Eur J Cancer. 2023 Oct 7;195:113371. doi: 10.1016/j...
Meric F, Hung MC, Hortobagyi GN, Hunt KK (2002) HER2/neu in the management of invasive breast cancer. Jour- nal of the American College of Surgeons 194(4): 488-501.Meric F, Hung MC, Hortobagyi GN, Hunt KK. HER2/neu in the management of invasive breast cancer. J Am Coll Surg ...
[1]ulrika pellas,annette bauer,ilija vladimir baroš, et al. her2-low metastases of her2-negative primary tumors: a single institution analysis of intertumoral and internodal heterogeneity in node-positive breast cancer.f...
[17] Scott M, Vandenberghe M, Scorer P, et al. Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay. 2021 ASCO.1021. [18] Corgiat B, O'Shaughnessy J, LoRusso P, et ...
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
[3]Slamon DJ,et al.Human breast cancer:correlation of relapse and survival with amplifcation of the HER-2/neuoncogene.Science 1987;235:177–82. [4]Eiger D,et al.The Exciting New Field of HER2-Low Breast Cancer Treatment.Cancers 2021;13:1015. ...